Zydus gets DCGI approval for phase-3 clinical trials of Covid-19 therapy

Trials will involve use of Cadila's biological therapy Pegylated Interferon alpha-2b in India

Cadila Healthcare Ltd (Zydus Cadila) has obtained approval from the Drugs Controller General of India (DCGI) to start the phase-3 clinical trial on Covid-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’.

Last month, Zydus Cadila had announced "successful" completion of phase two clinical trial of the biological therapy on Covid-19 patients, paving way for phase three trials in India. Cadila had stated that the open-label, randomized, comparator controlled study was conducted on 40 adult patients with moderate Covid-19 disease.

Of these, 95 per cent subjects in the test who received a single dose of PegiHepTM along with standard